LifeMD, Inc. (LFMDP)
| Market Cap | 236.01M -27.8% |
| Revenue (ttm) | 193.33M +19.7% |
| Net Income | 2.56M |
| EPS | 0.06 |
| Shares Out | 48.36M |
| PE Ratio | 92.23 |
| Forward PE | 33.36 |
| Dividend | $2.22 (9.58%) |
| Ex-Dividend Date | Jul 2, 2026 |
| Volume | 1,973 |
| Open | 23.00 |
| Previous Close | 23.01 |
| Day's Range | 23.00 - 23.28 |
| 52-Week Range | 18.50 - 24.34 |
| Beta | 1.99 |
| Analysts | n/a |
| Price Target | n/a |
| Earnings Date | Aug 4, 2026 |
About LFMDP
LifeMD, Inc. operates as a direct-to-patient telehealth company, engages in the provision of patients access to virtual medical care and pharmacy services in the United States. It offers telehealth platform comprising Rex MD, a men’s telehealth platform that provides virtual diagnosis, treatment, and prescription medications for men’s health conditions, including erectile dysfunction, premature ejaculation, hair loss, insomnia, weight loss, and performance anxiety; and ShapiroMD that provides virtual medical treatment, prescription medications,... [Read more]
News
LifeMD Declares Quarterly Dividend on Series A Cumulative Perpetual Preferred Stock
NEW YORK, June 23, 2026 (GLOBE NEWSWIRE) -- LifeMD, Inc. (Nasdaq: LFMD), a leading direct-to-patient telehealth company, today announced that its Board of Directors has authorized a cash dividend to h...
LifeMD partners with Halozyme subsidiary for exclusive testosterone program
LifeMD (LFMD) announced a strategic co-marketing collaboration with Antares Pharma, a subsidiary of Halozyme (HALO), supporting a direct-to-patient self-pay program for Xyosted. Under the agreement, L...
LifeMD Announces Exclusive Collaboration to Launch Direct-to-Patient Self-Pay Program for XYOSTED® (testosterone enanthate) Injection
Landmark agreement between a leading virtual care company and a pharmaceutical manufacturer establishes an exclusive telehealth co-marketing arrangement with LifeMD for the XYOSTED self-pay program, l...
LifeMD appoints Umesh Sripad as chief technology officer
LifeMD (LFMD) announced the appointment of Umesh Sripad as chief technology officer, or CTO, effective immediately. In this role, Sripad will lead LifeMD’s technology strategy, platform transformation...
LifeMD Appoints Umesh Sripad as Chief Technology Officer
Seasoned Technology Executive Brings More Than Two Decades of Large-Scale Digital Transformation Experience to Support LifeMD's Next Phase of Growth Seasoned Technology Executive Brings More Than Two ...
LifeMD Transcript: 16th Annual LD Micro Invitational Conference
A leading virtual care provider is expanding from men's health into high-growth areas like GLP-1 weight management, women's health, psychiatry, and cardiology, leveraging proprietary AI and integrated pharmacy infrastructure. Strong revenue growth, high margins, and a shift toward insurance coverage position the business for continued expansion and profitability.
LifeMD to Participate in Upcoming Investor Conferences
NEW YORK, May 15, 2026 (GLOBE NEWSWIRE) -- LifeMD, Inc. (Nasdaq: LFMD), a leading platform for virtual primary care services, today announced that management will be participating in two upcoming inve...
LifeMD Slides: Investor presentation
LifeMD has posted slides in relation to its latest quarterly earnings report, which was published on May 7, 2026.
LifeMD reports Q1 EPS (20c), consensus (12c)
Reports Q1 revenue $50.16M, consensus $48.88M. “Q1 was a strong start to 2026. We added more than 42,000 net telehealth subscribers, the largest quarterly net addition in our history. We…
LifeMD sees Q2 revenue $47M-$50M, consensus $53.74M
Sees Q2 adjusted EBITDA loss of $2M to gain of $1M.
LifeMD backs FY26 revenue view $220M-$230M, consensus $223.59M
Backs FY26 adjusted EBITDA $12M-$17M. “The first quarter played out largely as we expected: strong subscriber momentum, following a planned step-up in patient acquisition spend, and the early benefits...
LifeMD Earnings Call Transcript: Q1 2026
Q1 2026 saw revenue of $50.2M, record subscriber growth, and strong momentum in weight management and women's health. Gross margin expanded to 88%, and full-year guidance was reaffirmed, with profitability expected in the second half as acquisition costs decline.
LifeMD Earnings release: Q1 2026
LifeMD released its Q1 2026 earnings on May 6, 2026, summarizing the period's financial results.
LifeMD Slides: Q1 2026
LifeMD has posted slides in relation to its Q1 2026 quarterly earnings report, which was published on May 6, 2026.
LifeMD Quarterly report: Q1 2026
LifeMD has published its Q1 2026 quarterly earnings report on May 6, 2026.
LifeMD Reports First Quarter 2026 Results
First quarter 2026 revenue of $50.2 million and adjusted EBITDA loss of $4.5 million, above and in line, respectively, with the Company's guidance. Gross margin increased approximately 420 basis point...
LifeMD Proxy statement: Proxy filing
LifeMD filed a proxy statement on April 30, 2026, providing details for shareholder voting and corporate governance matters.
LifeMD Proxy statement: Proxy filing
LifeMD filed a proxy statement on April 30, 2026, providing details for shareholder voting and corporate governance matters.
LifeMD Proxy statement: Proxy filing
LifeMD filed a proxy statement on April 30, 2026, providing details for shareholder voting and corporate governance matters.
LifeMD to Report First Quarter 2026 Financial Results on May 6
NEW YORK, April 27, 2026 (GLOBE NEWSWIRE) -- LifeMD, Inc. (Nasdaq: LFMD), a leading provider of virtual primary care services, announces that it will report financial results for the three months ende...
LifeMD management to meet with BTIG
Meeting to be held in the Mid-Atlantic region on April 29-30 hosted by BTIG.
LifeMD now offering Foundayo from Eli Lilly
LifeMD (LFMD) announced that it is now offering Foundayo to eligible patients through its weight management program. Foundayo, developed by Eli Lilly (LLY), is a once daily oral treatment for…
LifeMD® Now Offering Eli Lilly and Company's Foundayo™ (orforglipron), a New GLP-1 Pill for Weight Management
LifeMD expands its weight management program with the addition of Foundayo, offering eligible patients an oral alternative to injectable GLP-1 therapies through LillyDirect® LifeMD expands its weight ...
LifeMD announces launch of Wegovy subscription program
LifeMD (LFMD) announced the launch of Novo Nordisk’s (NVO) new Wegovy subscription program is now available through LifeMD. “The program meaningfully expands patient access to branded GLP-1 therapy an...
LifeMD Offers Novo Nordisk's Industry-First Wegovy® Telehealth Subscription Program
Delivering up to $1,200 in annual patient savings on branded GLP-1 therapy, expanding LifeMD's collaboration with Novo Nordisk Delivering up to $1,200 in annual patient savings on branded GLP-1 therap...